Go to Where the Patients Are
This article was originally published in Start Up
Executive Summary
Novirio plans to do clinical trials in China for its hepatitis B treatment. Though developing nations are not generally considered capable of generating quality data, Novirio is betting that close management will yield data it can submit to FDA and leverage in Asia, where most of the patient population resides. It's a move to boost marketability against a competing drug from Glaxo.
You may also be interested in...
Novartis and Idenix Pursue Interdependent Growth
Novartis has capped a recent dealmaking spree with its most innovative deal yet--a half-acquisition of, half-alliance with, Idenix Pharmaceuticals. The big Swiss company agreed to pay $255 million to acquire a 51% equity stake in the private biotech company.
Super-Specialist CROs: Commercializing Pharma R&D Expertise
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.